Toripalimab + gemcitabine + cisplatin (JUPITER-02) — 1L recurrent/metastatic nasopharyngeal carcinoma

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-TORIPALIMAB` `DRUG-GEMCITABINE` `DRUG-CISPLATIN`

ID	`REG-NPC-GC-TORIPALIMAB`
Type	Regimen
Status	reviewed 2026-07-11 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-JUPITER-02-MAI-2021`

Notes

STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; dev-mode-exempted). JUPITER-02 (Mai HQ et al., Nat Med 2021, NCT03581786): toripalimab + gemcitabine/cisplatin vs placebo + gemcitabine/cisplatin in treatment-naive recurrent/metastatic NPC. Approximate reported results (pending verification against primary source): mPFS ~11.7 vs ~8.0 months (HR ~0.52), ORR ~77% vs ~66%; a later analysis reportedly also showed an OS benefit. FDA-approved (Loqtorzi) Oct 2023 specifically for this indication. Camrelizumab + GP (REG-NPC-GC-CAMRELIZUMAB, CAPTAIN-1st) is an equally evidence-supported alternative — see IND-NPC-1L-METASTATIC-GC-PD1 known_controversies for the toripalimab-vs-camrelizumab access/ evidence discussion.

Used By

Indication

IND-NPC-1L-METASTATIC-GC-PD1 - IND-NPC-1L-METASTATIC-GC-PD1

Regimen

REG-NPC-GC-CAMRELIZUMAB - Camrelizumab + gemcitabine + cisplatin (CAPTAIN-1st) — 1L recurrent/metastatic nasopharyn...